This article aggregates 35+ questions patients commonly ask about psilocybin-assisted therapy in Canada. For deeper coverage of any topic, follow the cross-links to the relevant cluster articles. Compliance reminders: psilocybin is Schedule III under the CDSA with no Health Canada approved indication. Clinical access is via the Special Access Program (SAP) only since the January 5, 2022 amendment. Recreational possession is illegal. This article reflects the honest 2026 Canadian landscape.
Quick navigation:
The basics — what psilocybin therapy is and how it works {#the-basics}
1. What is psilocybin therapy? Psilocybin-assisted therapy is a structured clinical model that pairs a high-dose psilocybin session (typically 25 mg of synthetic pharmaceutical psilocybin) with preparation sessions before and integration sessions afterward. The dosing session runs 6–8 hours in a clinical setting with two trained therapists in most published trial protocols. See What Is Psilocybin Therapy?.
2. How does psilocybin work? Psilocybin is converted in the body to psilocin, which acts as a partial agonist at 5-HT2A serotonin receptors. Downstream effects include default mode network modulation, neuroplasticity (Ly 2018), and the mystical-type experience that mediates therapeutic outcomes (Roseman 2018, MacLean 2011). See What Is Psilocybin Therapy? and How Psilocybin-Assisted Psychotherapy Works.
3. Is this just taking magic mushrooms with a guide? No. Clinical psilocybin therapy uses synthetic pharmaceutical-grade psilocybin (typically Filament Health's PEX010 or imported COMP360), is delivered in a CDSA-compliant clinical setting under SAP authorization, includes structured preparation and integration psychotherapy, and is bound by professional clinical standards. Recreational mushroom use with a guide outside this framework is not psilocybin therapy.
4. Why are two therapists usually present? Most published trial protocols use two trained therapists during dosing for continuity of presence (6–8 hours is too long for one therapist), patient–therapist match (some protocols use male-female dyads), safety redundancy, and therapeutic depth. Some Canadian clinical models use one therapist + medical staff. See How Psilocybin-Assisted Psychotherapy Works.
5. How is this different from recreational mushrooms? Synthetic pharmaceutical psilocybin has known purity, exact dose, supervised setting, screened patients, and integration support. Recreational mushrooms have variable potency, no clinical screening, no integration, and are illegal to possess. The legal, pharmacological, and clinical contexts are fundamentally different.
Access and the SAP pathway {#access}
6. Is psilocybin therapy legal in Canada? Yes — when accessed through Health Canada's Special Access Program (SAP). The legal pathway has been operational since the January 5, 2022 SAP amendment. Recreational possession remains illegal. See Is Psilocybin Legal in Canada?.
7. How does the SAP pathway work? A licensed physician or nurse practitioner submits a case-specific SAP request on behalf of an individual patient with a serious or life-threatening condition where conventional treatments have failed. Patients cannot apply directly. See How to Access Psilocybin Therapy in Canada.
8. Can I apply for SAP myself? No. SAP applications are physician- or nurse-practitioner-initiated. You need a willing prescriber. TheraPsil maintains a directory of trained Canadian clinicians and offers free patient consultations.
9. How long does SAP review take? Historically 1–4 weeks; lengthening through 2025 per PsyCan reporting. Plan for 2–8 weeks or longer in 2026.
10. What's the SAP approval rate? Historical psilocybin SAP approval rates were ~78% per industry reporting through 2024. PsyCan's September 2025 report documented a sharp decline through 2025. Cumulative approvals reached ~301 by mid-2025.
11. What conditions are SAP-approved for? End-of-life distress (most common; foundation indication), treatment-resistant depression, alcohol use disorder, demoralization, cluster headache, OCD, anorexia, others case-by-case.
12. Where does the drug come from? Health Canada-licensed Canadian producers: Filament Health (often provides drug at no charge to SAP patients), Optimi Health, Psyence Group; some imported Compass Pathways COMP360.
13. Does my GP have to apply for SAP? No — any licensed physician or NP can apply. In practice, applications are usually initiated by psychiatrists, palliative-care physicians, or addiction-medicine physicians familiar with the SAP framework.
14. What if my doctor refuses to apply? This is the most common bottleneck. TheraPsil and other Canadian organizations help patients find willing prescribers. The ATMA CENA intake call can orient you to appropriate resources.
Evidence by indication {#evidence}
15. What's the strongest published evidence? End-of-life distress (Griffiths 2016 N=51, Ross 2016 N=29, Agin-Liebes 2020 long-term follow-up, Agrawal 2024 group format) and TRD (Goodwin 2022 NEJM COMP001 N=233, Davis 2021, Carhart-Harris 2021 NEJM vs escitalopram). The AUD evidence (Bogenschutz 2022 JAMA Psychiatry N=95) is the cleanest single SUD trial.
16. Is psilocybin good for depression? For treatment-resistant depression specifically, yes — supported by Goodwin 2022, Davis 2021, Carhart-Harris 2016/2021. The evidence base is real but smaller than ketamine TRD evidence; CANMAT does not yet include psilocybin in TRD recommendations. See Psilocybin Therapy for TRD.
17. Is psilocybin good for anxiety? The strongest evidence is in cancer-related anxiety (Griffiths 2016, Ross 2016). Primary anxiety disorder (GAD, SAD) evidence is preliminary. Ketamine has more developed primary-anxiety evidence (Glue trials, Whittaker 2021 meta). See Psilocybin Therapy for Anxiety.
18. Is psilocybin good for PTSD? Limited PTSD-specific psilocybin evidence. PTSD-specific Canadian SAP applications more commonly target MDMA-assisted therapy (Mitchell 2021/2023 MAPP1/MAPP2 Phase 3 trials).
19. Is psilocybin good for alcohol use disorder? Yes — Bogenschutz 2022 is the strongest psychedelic SUD trial published. But active SUD is normally a contraindication; psilocybin is positioned as adjunctive consolidation in stabilized recovery, not as detox or first-line treatment. See Psilocybin Therapy for AUD.
20. Is psilocybin good for end-of-life distress? This is where the evidence is strongest. Griffiths 2016, Ross 2016, Agin-Liebes 2020 4–5 year follow-up with sustained response. Foundation indication for Canadian SAP approvals. See Psilocybin Therapy for End-of-Life Distress.
21. Is psilocybin good for demoralization? Yes — Anderson 2020 EClinicalMedicine pilot in long-term AIDS-survivor men showed clinically meaningful improvement. Demoralization is distinct from depression and is recognized as a SAP-eligible indication in serious-illness contexts. See Psilocybin Therapy for Demoralization.
Cost and insurance {#cost}
22. How much does psilocybin therapy cost in Canada? Typically CAD $2,500–$6,500 per program out-of-pocket, including preparation, dosing day, and integration. Filament Health often supplies SAP-approved psilocybin at no charge — meaningful Canadian-specific cost reduction. See Psilocybin-Assisted Therapy Cost in Canada.
23. Does insurance cover psilocybin therapy? Generally no. Quebec RAMQ has a public-funding precedent (Farzin/Stephan December 2022). VAC does NOT cover psilocybin (different from ketamine). Private insurance: drug not covered; therapy fees may be partially covered as standard psychotherapy.
24. Why is the drug often free? Filament Health, Canada's first DEA-licensed natural psilocybin producer, has consistently provided synthetic psilocybin to SAP-approved patients at no charge as a public-good model. Not every SAP patient receives this, but it is common.
25. Does Quebec really cover psilocybin therapy publicly? Yes — Drs. Houman Farzin and Jean-François Stephan billed RAMQ in December 2022 for SAP-approved psilocybin-assisted therapy. RAMQ subsequently modified billing codes for further claims. Quebec is the only province with this precedent. See Psilocybin Therapy in Quebec.
26. Does VAC cover psilocybin for veterans? No — VAC does not currently cover psilocybin-assisted therapy. This is a meaningful contrast to ketamine, which VAC does cover for service-related TRD or chronic pain.
27. Does Alberta Blue Cross PAT cover psilocybin? The March 2024 Alberta Blue Cross PAT coverage applied to ketamine-assisted therapy. Psilocybin coverage was framed as future potential once formally legalized. Confirm current scope with Alberta Blue Cross.
The session experience {#session}
28. How long does a psilocybin session last? 6–8 hours total in clinic. Onset 20–50 min after dose; peak 1.5–3 hours; comedown 3–5 hours; total experience 4–6 hours plus initial settling and post-session observation. See What to Expect at a Psilocybin Session.
29. What does the dosing session feel like? Visual changes (geometric patterns, enhanced colour), time distortion, emotional intensity, ego dissolution at higher doses, mystical-type experience (oceanic boundlessness, sense of unity, transcendence). Often includes challenging moments. Most patients lie down with eye shades and music.
30. Can I drive home afterward? No. 24-hour no-driving rule is universal. Designated driver required.
31. How many sessions are typical? Most published TRD trials use 1–2 dosing sessions. End-of-life distress trials typically use 1 session. AUD trials (Bogenschutz 2022) used 2 sessions. Plus 2–3 preparation sessions and 2–4 integration sessions.
32. Will I need to do this more than once? Many patients have meaningful sustained response from one or two sessions. Some patients return for additional courses over time. Long-term durability varies; the Agin-Liebes 2020 4–5 year follow-up showed sustained response in a meaningful subset.
33. What if I have a difficult experience? Difficult experiences (fear, grief, body horror) are common and often productive. The therapy team practices non-directive presence; integration sessions are where challenging content becomes meaningful. Most challenging experiences resolve with appropriate set/setting and integration. See Psilocybin Side Effects and Safety.
Safety and side effects {#safety}
34. Is psilocybin therapy safe? At therapeutic supervised doses with appropriate pre-treatment screening, the safety profile is well-characterized: most side effects are transient and resolve within hours-to-days. Serious adverse events in published trials have been rare. See Psilocybin Side Effects and Safety.
35. What are the most common side effects? Mild-to-moderate nausea (~50% of sessions), transient blood pressure and heart rate elevation, mild headache, fatigue afterward, and the experiential intensity itself (challenging moments). Most resolve within hours.
36. What are the absolute contraindications? Personal history of psychotic disorder; first-degree family history of psychotic disorder; active mania or recent hypomania; uncontrolled cardiovascular disease; recent MI; pregnancy; concurrent lithium (seizure case reports).
37. Can I take psilocybin if I'm on an SSRI? This is a clinical decision with the prescribing physician. Many trial protocols taper SSRIs before dosing under supervision. Some clinical models continue lower-dose SSRI through dosing. Specific approach is individualized.
38. What about lithium? Concurrent lithium is treated as an absolute contraindication due to seizure case reports. Patients on lithium pursuing psilocybin SAP do so only after carefully managed taper under prescriber supervision, if at all.
39. What about tramadol? Tramadol carries serotonin syndrome risk with psilocybin and is flagged as a meaningful interaction. Discuss with your prescribing physician and pain provider before psilocybin work.
40. Will psilocybin trigger psychosis? Personal history of psychotic disorder and first-degree family history are absolute contraindications precisely because of this concern. In screened populations without these risk factors, psychosis emerging from clinical psilocybin therapy has been very rare across published trials.
41. Is psilocybin addictive? Psilocybin has very low abuse potential — substantially lower than most controlled substances. The single-or-two-dose clinical protocol does not create exposure conditions associated with dependence. No take-home dispensing under SAP.
Microdosing {#microdosing}
42. Does microdosing work? The published rigorous placebo-controlled evidence (Szigeti 2021 eLife) suggests microdosing benefits are largely placebo-mediated. Self-report studies report subjective benefits but cannot disentangle pharmacological effects from expectancy. See Microdosing Psilocybin.
43. Is microdosing legal in Canada? No. Recreational possession of psilocybin is illegal under CDSA Schedule III. Microdosing is not part of the SAP pathway.
44. Does ATMA CENA facilitate microdosing? No. ATMA CENA does not endorse, facilitate, or recommend microdosing as a clinical intervention. Patients interested in psilocybin's therapeutic potential are directed toward SAP-pathway high-dose protocols.
Comparing to ketamine {#vs-ketamine}
45. Should I do psilocybin or ketamine therapy? Depends on indication, access, coverage, and clinical fit. Ketamine has broader access, larger evidence base, and more insurance pathways. Psilocybin has stronger evidence in specific indications (end-of-life distress, AUD, demoralization) and Quebec public funding for eligible patients. See Psilocybin vs Ketamine Therapy.
46. Which has better evidence for TRD? Ketamine — much larger published RCT base, CANMAT 2021 task force recommendation, ELEKT-D 2023 NEJM head-to-head non-inferior to ECT. Psilocybin TRD evidence is meaningful but smaller (Goodwin 2022, Davis 2021, Carhart-Harris 2016/2021).
47. Which has better evidence for AUD? Psilocybin — Bogenschutz 2022 JAMA Psychiatry is the cleanest published psychedelic SUD trial.
48. Which is more accessible in Canada? Ketamine. Off-label legal across Canada plus Spravato Health Canada-approved for TRD plus VAC and workers' comp coverage. Psilocybin is SAP-only.
49. Which costs less out-of-pocket? For privately-insured patients, ketamine (particularly Spravato) is typically cheaper net out-of-pocket due to prior-auth coverage. List prices are similar; insurance coverage is the differentiator.
50. What's the experiential difference? Psilocybin: classic psychedelic — visuals, ego dissolution, mystical experience, longer (6–8 hour) session. Ketamine: dissociative — softening of body awareness, time distortion, shorter (90–120 min) session.
Quebec specifics {#quebec}
51. Why does Quebec have public funding when other provinces don't? The December 2022 Farzin/Stephan billing was the first instance of any province's medicare system processing a psilocybin-assisted therapy claim. RAMQ subsequently modified billing codes. Other provincial drug plans have not followed. See Psilocybin Therapy in Quebec.
52. Do I need to be a Quebec resident for the RAMQ pathway? Yes — RAMQ coverage requires Quebec residency. Non-Quebec residents pursuing psilocybin SAP face the standard out-of-pocket cost.
53. What does Quebec's Bill 21 mean for me? The psychotherapy component of psilocybin-assisted therapy must be delivered by a physician, psychologist, or OPQ psychotherapy permit holder. Unregulated coaches or counsellors cannot deliver the psychotherapy component in Quebec.
How ATMA CENA fits {#provider}
54. Does ATMA CENA directly administer psilocybin? The medical SAP application is initiated by the patient's prescribing physician — not ATMA CENA directly. ATMA CENA supports preparation and integration through the three-phase psychedelic-assisted therapy model in coordination with the prescribing physician.
55. What's the coordinated care model? ATMA CENA's care coordination model lets your existing therapist remain the primary therapeutic relationship while ATMA CENA's clinical infrastructure provides the dosing-specific frame. Particularly relevant for SAP-pathway patients with established prescribing physician relationships.
56. Can my existing therapist work with me through ATMA CENA? Yes — through coordinated care. In Quebec, your therapist must meet Bill 21 requirements (physician, psychologist, or OPQ permit holder). In other provinces, regulated psychotherapists, psychologists, and clinical counsellors generally fit.
57. Does ATMA CENA initiate SAP applications? No. The medical SAP application is initiated by the patient's prescribing physician or nurse practitioner. ATMA CENA's clinical team can discuss the regulatory framework and how preparation/integration would fit.
58. Where are ATMA CENA's clinics? Corporate clinics in Edmonton and Calgary; member clinics across multiple provinces. Confirm specific psilocybin-pathway scope at intake.
What to do next {#next-steps}
59. What's the first step?
60. What if I don't have a prescribing physician? TheraPsil maintains a directory of trained Canadian clinicians and offers free patient consultations to help match patients with prescribing physicians. The ATMA CENA intake call can orient you to appropriate Canadian resources.
61. What if I'm not a candidate for psilocybin? Many patients pursuing psychedelic-assisted therapy are better served by ketamine — broader access, larger evidence base, Spravato pathway with private insurance coverage. The ATMA CENA intake call discusses both pathways honestly.
62. What if I've already been microdosing? Discuss with the prescribing physician you're considering. Most clinical protocols would prefer washout before high-dose SAP-pathway work.
63. What about end-of-life patients with limited time? The standard three-phase model can be compressed for patients with shorter prognosis. Some Canadian palliative protocols use abbreviated preparation (1–2 sessions over 1–2 weeks) and integration adjusted to remaining time. See Psilocybin Therapy for End-of-Life Distress.
64. Where can I learn more? The full mushroom cluster covers each topic in depth:
- Foundation: Psilocybin Therapy in Canada, What Is Psilocybin Therapy?
- Access: How to Access Psilocybin Therapy in Canada (SAP), Health Canada SAP Deep Dive
- Cost: Psilocybin-Assisted Therapy Cost in Canada
- Indications: End-of-Life Distress, TRD, AUD, Anxiety, Demoralization
- Modality: How Psilocybin-Assisted Psychotherapy Works, What to Expect at a Session
- Safety: Psilocybin Side Effects and Safety
- Microdosing: Microdosing Psilocybin
- Legality: Is Psilocybin Legal in Canada?
- Quebec: Psilocybin Therapy in Quebec
- Comparison: Psilocybin vs Ketamine Therapy
Sources
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
- Ross S, et al. (2016). Psilocybin in cancer-related anxiety/depression. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909165/
- Goodwin GM, et al. (2022). COMP360 psilocybin in TRD Phase 2b. NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
- Davis AK, et al. (2021). Psilocybin for MDD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33146667/
- Bogenschutz MP, et al. (2022). Psilocybin for AUD. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625
- Anderson BT, et al. (2020). Psilocybin-assisted group therapy for demoralization. EClinicalMedicine. https://pubmed.ncbi.nlm.nih.gov/33150319/
- Szigeti B, et al. (2021). Self-blinding placebo-controlled microdosing study. eLife. https://pubmed.ncbi.nlm.nih.gov/33648632/
- TheraPsil: https://therapsil.ca/
- PsyCan / Psychedelics Canada: https://psychedelicscanada.org/
- Filament Health: https://filament.health/
Related articles
All cluster articles are linked above by topic. The hub at Psilocybin Therapy in Canada is the cluster entry point.
Last updated: 2026-05-06